Effects of astragaloside IV against the TGF-β1-induced epithelial-to-mesenchymal transition in peritoneal mesothelial cells by promoting Smad 7 expression

Cellular Physiology and Biochemistry

Volumn 37, Issue 1, 2015, Pages 43-54

  Zhang, Lu ^a,b   Li, Zhenghong ^b   He, Weiming ^b   Xu, Lingdong ^b   Wang, Jing ^c   Shi, Jun ^a   Sheng, Meixiao ^a,b  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c Jiangsu Provincial Hospital of Chinese Medicine   (China)

Author keywords

Astragaloside IV; EMT; Mesothelial cells; Peritoneal dialysis (PD); Peritoneal fibrosis (PF); Smad7; TGF 1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ASTRAGALOSIDE IV; COLLAGEN TYPE 1; REACTIVE OXYGEN METABOLITE; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; SNAIL1 PROTEIN; SNAIL2 PROTEIN; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; ACTA2 PROTEIN, HUMAN; ACTIN; ASTRAGALOSIDE A; CADHERIN; SAPONIN; SMAD7 PROTEIN, HUMAN; TRITERPENE;

ARTICLE; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LENTIVIRINAE; MESOTHELIUM CELL; PERITONEUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; CELL LINE; CELL MOTION; DRUG EFFECTS; EPITHELIUM; METABOLISM;

ACTINS; CADHERINS; CELL LINE; CELL MOVEMENT; COLLAGEN TYPE I; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; EPITHELIUM; GENE EXPRESSION; HUMANS; SAPONINS; SIGNAL TRANSDUCTION; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TRITERPENES; UP-REGULATION; VIMENTIN;

EID: 84939482621     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000430332     Document Type: Article

References (43)

1. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, Kasiske B, Kutner N, Liu J, St Peter W, Guo H, Gustafson S, Heubner B, Lamb K, Li S, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Thompson B, Wang C, Weinhandl E, Zaun D, Arko C, Chen SC, Daniels F, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers P, Agodoa L: United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Am J Kidney Dis 2012;59:7, e1-420
2. Davies SJ, Phillips L, Griffiths AM, Russell LH, Naish PF, Russell GI: What really happens to people on long-term peritoneal dialysis? Kidney Int 1998;54:2207-2217
3. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT; Peritoneal Biopsy StudyGroup: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13:470-479
4. Devuyst O, Margetts PJ, Topley N: The pathophysiology of the peritoneal membrane. J Am Soc Nephrol 2010;21:1077-1085
5. Shimaoka T, Hamada C, Kaneko K, Io H, Sekiguchi Y, Aruga S, Inuma J, Inami Y, Hotta Y, Horikoshi S, Kumasaka T, Tomino Y: Quantitative evaluation and assessment of peritoneal morphologic changes in peritoneal dialysis patients. Nephrol Dial Transplant 2010;25:3379-3385
6. Smit W, Schouten N, van den Berg N, Langedijk MJ, Struijk DG, Krediet RT ;Netherlands Ultrafiltra¬tion Failure Study Group: Analysis of the prevalence and causes of ultrafiltration failure during long-term perito-neal dialysis: a cross-sectional study. Perit Dial Int 2004;24:562-570
7. Farhat K, Stavenuiter AW, Beelen RH, Ter Wee PM: Pharmacologic targets and peritoneal membrane remodeling. Perit Dial Int 2014;34:114-123
8. Diao JN, Sheng MX, Zhu XX, Wang NJ, Zhu CL, He WM: Huangqi (Astragalus membranaceus) injections could improve the dialysis efficiency and reduce peritoneal fibrosis in high permeable peritoneal dialysis treated rats (In Chinese). Nan Jing Zhong Yi Yao Da Xue Xue Bao 2011;27:58-62
9. Yang HT, Shang YC, Cao SL, Dou YT, Huang Y: Effect of shenshuning recipe on the extracellular matrix accumulation of the peritoneal fibrosis rats (in Chinese). Zhongguo Zhong Xi Yi Jie He Za Zhi 2013;33:1683-1689
10. Li Z, Zhang L, He W, Zhu C, Yang J, Sheng M: Astragalus membranaceus inhibits peritoneal fibrosis via monocyte chemoattractant protein (MCP)-1 and the transforming growth factor-β1 (TGF-β1) pathway in rats submitted to peritoneal dialysis. Int J Mol Sci 2014; 15:12959-12971
11. Polat E, Bedir E, Perrone A, Piacente S, Alankus-Caliskan O:Triterpenoid saponins from Astragalus wiedemannianus Fischer. Phytochemistry 2010;71:658-662
12. Chen X, Peng LH, Li N, Li QM, Li P, Fung KP, Leung PC, Gao JQ: The healing and anti-scar effects of astragaloside IV on the wound repair in vitro and in vivo. J Ethnopharmacol 2012;139:721-727
13. Xu W, Shao X, Tian L, Gu L, Zhang M, Wang Q, Wu B, Wang L, Yao J, Xu X, Mou S, Ni Z:Astragaloside IV ameliorates renal fibrosis via the inhibition of mitogen-activated protein kinases and antiapoptosis in vivo and in vitro. J Pharmacol Exp Ther 2014;350:552-562
14. Li X, Wang X, Han C, Wang X, Xing G, Zhou L, Li G, Niu Y: Astragaloside IV suppresses collagen production of activated hepatic stellate cells via oxidative stress-mediated p38 MAPK pathway. Free Radic Biol Med 2013;60:168-176
15. Chen P, Xie Y, Shen E, Li GG, Yu Y, Zhang CB, Yang Y, Zou Y, Ge J, Chen R, Chen H: Astragaloside IV attenuates myocardial fibrosis by inhibiting TGF-β1 signaling in coxsackievirus B3-induced cardiomyopathy. Eur J Pharmacol 2011;658:168-174
16. Wang L, Chi YF, Yuan ZT, Zhou WC, Yin PH, Zhang XM, Peng W: Astragaloside IV inhibits the up-regulation of Wnt/β-catenin signaling in rats with unilateral ureteral obstruction. Cell Physiol Biochem. 2014;33:1316-1328
17. Lamouille S, Xu J, Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014;15:178-196
18. Xu J, Lamouille S, Derynck R: TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009;19:156-172
19. Strippoli R, Loureiro J, Moreno V, Benedicto I, Perez Lozano ML, Barreiro O, Pellinen T, Minguet S, Foronda M, Osteso MT, Calvo E, Vazquez J, Lopez Cabrera M, Del Pozo MA: Caveolin-1 deficiency induces a MEK-ERK1/2-Snail-1-dependent epithelial-mesenchymal transition and fibrosis during peritoneal dialysis. EMBO Mol Med 2014;7:102-123
20. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-Jimenez C, Jimenez-Heffernan JA, Aguilera A, Sanchez-Tomero JA, Bajo MA, Alvarez V, Castro MA, del Peso G, Cirujeda A, Gamallo C, Sanchez-Madrid F, Lopez-Cabrera M : Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003;348:403-413
21. Pletinck A, Vanholder R, Veys N, Van Biesen W: Protecting the peritoneal membrane: factors beyond peritoneal dialysis solutions. Nat Rev Nephrol 2012;8:542-550
22. Goodlad C, Brown EA: Encapsulating peritoneal sclerosis: what have we learned? Semin Nephrol 2011;31:183-198
23. Gonzalez DM, Medici D: Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal 2014;7:re8
24. Okado T, Terada Y, Tanaka H, Inoshita S, Nakao A, Sasaki S: Smad7 mediates transforming growth factor-beta-induced apoptosis in mesangial cells. Kidney Int 2002;62:1178-1186
25. Nakamoto H, Kawaguchi Y, Suzuki H: Is technique survival on peritoneal dialysis better in Japan? Perit Dial Int 2006;26:136-143
26. Strippoli R, Benedicto I, Perez Lozano ML, Pellinen T, Sandoval P, Lopez-Cabrera M, del Pozo MA: Inhibition of transforming growth factor-activated kinase 1 (TAK1) blocks and reverses epithelial to mesenchymal transition of mesothelial cells. PLoS One 2012;7:e31492
27. Pang L, Li Q, Wei C, Zou H, Li S, Cao W, He J, Zhou Y, Ju X, Lan J, Wei Y, Wang C, Zhao W, Hu J, Jia W, Qi Y, Liu F, Jiang J, Li L, Zhao J, Liang W, Xie J, Li F:TGF-β1/Smad signaling pathway regulates epithelial-to-mesenchymal transition in esophageal squamous cell carcinoma: in vitro and clinical analyses of cell lines and nomadic Kazakh patients from northwest Xinjiang, China. PLoS One 2014;9:e112300
28. Geng J, Fan J, Ouyang Q, Zhang X, Zhang X, Yu J, Xu Z, Li Q, Yao X, Liu X, Zheng J: Loss of PPM1A expression enhances invasion and the epithelial-to-mesenchymal transition in bladder cancer by activating the TGF-β/Smad signaling pathway. Oncotarget 2014;5:5700-5711
29. Rodrigues-Diez R, Rodrigues-Diez RR, Lavoz C, Carvajal G, Droguett A, Garcia-Redondo AB, Rodriguez I, Ortiz A, Egido J, Mezzano S, Ruiz-Ortega M: Gremlin activates the Smad pathway linked to epithelial mesenchymal transdifferentiation in cultured tubular epithelial cells. Biomed Res Int 2014;2014:802841
30. Wang L, Chi YF, Yuan ZT, Zhou WC, Yin PH, Zhang XM, Peng W, Cai H: Astragaloside IV inhibits renal tubulointerstitial fibrosis by blocking TGF-β/Smad signaling pathway in vivo and in vitro. Exp Biol Med (Maywood) 2014;239:1310-1324
31. Park SH, Jung EH, Kim GY, Kim BC, Lim JH, Woo CH:Itch E3 Ubiquitin Ligase Positively Regulates TGF-β Signaling to EMT via Smad7 Ubiquitination. Mol Cells 2015;38:20-25
32. Ka SM, Yeh YC, Huang XR, Chao TK, Hung YJ, Yu CP, Lin TJ, Wu CC, Lan HY, Chen A: Kidney-targeting Smad7 gene transfer inhibits renal TGF-β/MAD homologue (SMAD) and nuclear factor κB (NF-κB) signalling pathways, and improves diabetic nephropathy in mice. Diabetologia 2012;55:509-519
33. Yan X, Zhang J, Pan L, Wang P, Xue H, Zhang L, Gao X, Zhao X, Ning Y, Chen YG: TSC-22 promotes transforming growth factor β-mediated cardiac myofibroblast differentiation by antagonizing Smad7 activity. Mol Cell Biol 2011;31:3700-3709
34. Kokkinakis DM, Liu X, Chada S, Ahmed MM, Shareef MM, Singha UK, Yang S, Luo J:Modulation of gene expression in human central nervous system tumors under methionine deprivation-induced stress. Cancer Res 2004;64:7513-7525
35. Park SA, Kim MJ, Park SY, Kim JS, Lee SJ, Woo HA, Kim DK, Nam JS, Sheen YY: EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling. Cell Mol Life Sci 2015;72:2023-2039
36. Lu G, Xu S, Peng L, Huang Z, Wang Y, Gao X:Angiotensin II upregulates Kv1.5 expression through ROS-dependent transforming growth factor-beta1 and extracellular signal-regulated kinase 1/2 signalings in neonatal rat atrial myocytes. Biochem Biophys Res Commun 2014;454:410-416
37. Huang KT, Wu CT, Huang KH, Lin WC, Chen CM, Guan SS, Chiang CK, Liu SH: Titanium Nanoparticle Inhalation Induces Renal Fibrosis in Mice via an Oxidative Stress Upregulated Transforming Growth Factor-β Pathway. Chem Res Toxicol 2015;28:354-364
38. Choi YJ, Kim da H, Kim SJ, Kim J, Jeong SI, Chung CH, Yu KY, Kim SY: Decursin attenuates hepatic fibrogenesis through interrupting TGF-beta-mediated NAD(P)H oxidase activation and Smad signaling in vivo and in vitro. Life Sci 2014;108:94-103
39. Hu Y, He K, Wang D, Yuan X, Liu Y, Ji H, Song J:TMEPAI regulates EMT in lung cancer cells by modulating the ROS and IRS-1 signaling pathways. Carcinogenesis 2013;34:1764-72
40. Felton VM, Borok Z, Willis BC: N-acetylcysteine inhibits alveolar epithelial-mesenchymal transition. Am J Physiol Lung Cell Mol Physiol 2009;297:L805-812
41. Gui D, Guo Y, Wang F, Liu W, Chen J, Chen Y, Huang J, Wang N: Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo. PLoS One 2012;7:e39824
42. Sun L, Li W, Li W, Xiong L, Li G, Ma R:Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NFκB pathway under high glucose conditions. Int J Mol Med 2014;34:167-176
43. Bae SY, Kim HJ, Lee KJ, Lee K: Translationally Controlled Tumor Protein induces epithelial to mesenchymal transition and promotes cell migration, invasion and metastasis. Sci Rep 2015;5:8061